Risk factors for severe infections in secondary immunodeficiency: a retrospective US administrative claims study in patients with hematological malignancies

Stephen Jolles, B. Douglas Smith, Donald C. Vinh, Rajiv Mallick, Gabriela Espinoza, Mitchell DeKoven, Victoria Divino

Research output: Contribution to journalArticlepeer-review

Abstract

Real-world data are lacking to identify patients with secondary immunodeficiency (SID) who may benefit most from anti-infective interventions. This retrospective analysis used the IQVIA PharMetrics® Plus database to assess baseline characteristics associated with risk of severe infections post-SID diagnosis in patients with hematological malignancies. In 4066 patients included, the mean number of any and severe infections per patient in the one-year pre-SID diagnosis period was 9.5 and 0.7, respectively. Post-SID diagnosis, the mean annualized number of any and severe infections was 19.1 and 1.5, respectively. Receiver operating characteristic curve analysis identified a threshold (cutoff) of three bacterial infections at baseline as optimally predictive of severe infections post-SID diagnosis. Multivariate analysis indicated that hospitalizations, infections (≥3), or antibiotic use pre-SID diagnosis were predictive of severe infections post-SID diagnosis. Evaluation of these risk factors could inform clinical decisions regarding which patients may benefit from prophylactic anti-infective treatment, including immunoglobulin replacement if warranted.

Original languageEnglish (US)
Pages (from-to)64-73
Number of pages10
JournalLeukemia and Lymphoma
Volume63
Issue number1
DOIs
StatePublished - 2022

Keywords

  • Secondary infections
  • hematological malignancies
  • hypogammaglobulinemia
  • infection risk factors
  • secondary immunodeficiency

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Risk factors for severe infections in secondary immunodeficiency: a retrospective US administrative claims study in patients with hematological malignancies'. Together they form a unique fingerprint.

Cite this